Breast

GS-US-595-6184 at https://clinicaltrials.gov/study/NCT05633654

A randomized, open-label, phase 3 study of adjuvant sacituzumab govitecan (Trodelvy®) and pembrolizumab (Keytruda®) vs. treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy

Cancer Type: Breast triple negative

Principal Investigator: Dr. Debra Brandt

Please contact Clinical Trials Office for more details: 561-263-5791

NRG – S2010 at https://clinicaltrials.gov/study/NCT05568472

Randomized Ph III Trial comparing Active Symptom Monitoring plus Patient Education vrs Patient Education alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN)

Cancer Type: Breast, Stage I-III hormone receptor +

Principal Investigator: Dr. Debra Brandt

Please contact Clinical Trials Office for more details: 561-263-5791

NRG – S2212 at https://clinicaltrials.gov/study/NCT05929768

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer, a Randomized Phase III Study

Cancer Type: Triple Negative Breast Cancer

Principal Investigator: Dr. Debra Brandt

Please contact Clinical Trials Office for more details: 561-263-5791

NRG – S2206 at Study Details | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | ClinicalTrials.gov

Ph 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy vrs Chemotherapy Alone for Adults w/MammPrint Ultrahigh (MP2) HR + HER2- Stage II-III BC

Principal Investigator: Dr. Debra Brandt

Please contact Clinical Trials Office for more details: 561-263-5791